10 Best Penny Stocks That Could Triple Your Money

9. Akebia Therapeutics Inc. (NASDAQ:AKBA)

Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the 10 best penny stocks that could triple your money.

On February 26, Akebia Therapeutics Inc. (NASDAQ:AKBA) outlined its 2026 pipeline expansion and shared expectations for Vafseo data catalysts in the $1 billion dialysis market during its fourth quarter 2025 earnings call. The company reported a total of $227 million in net product revenue for the year, with Vafseo and Auryxia being major contributors.

Chief Executive Officer John Butler reported that it was an important year for Akebia, particularly due to the commercialization of Vafseo. He also reported that there is increasing evidence of Vafseo’s potential for becoming standard of care in what is a $1 billion U.S. opportunity post-TDAPA, when Vafseo is expected to be priced at about parity with ESA pricing.

The company also announced its pipeline for rare kidney diseases, including an R&D day scheduled for April 2 to discuss mid-stage assets such as praliciguat and AKB-097. Butler stated:

“At the ASN meeting in November, we presented a post-hoc hierarchical composite endpoint analysis where patients treated with Vafseo experienced a lower risk of dying or being hospitalized than patients treated with the ESA comparator.”

On February 25, BTIG reduced the firm’s price target on Akebia Therapeutics Inc. (NASDAQ:AKBA) from $5 to $4. The firm maintained its Buy rating on the stock, citing a new protocol from U.S. Renal Care that impacted dosing practices, leading to a decline in channel inventory and lower-than-expected Q4 revenue for Vafseo. It added that the inventory adjustment weighed on near-term results despite the company’s broader outlook remaining intact.

Akebia Therapeutics Inc. (NASDAQ:AKBA) concentrates on the development and commercialization of medicines for kidney diseases. Its product portfolio includes Vafseo (vadadustat) and Auryxia. Additionally, it is working on AKB-10108 for the treatment of retinopathy of prematurity in neonates and AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome, which is undergoing Phase 2 of its clinical trial.